Coloplast generated 7% organic revenue growth in the first half-year, with
growth rates of 11% in Q1 and of 4% in Q2. Forecasts for full-year organic
growth of about 8% and an EBIT margin at constant exchange rates of 16-17%
maintained.
Coloplast is the world's leading supplier of intimate healthcare products and
is consolidating its position by outperforming market growth.
“As expected, our half-year results were affected by lower sales in our German
homecare business. As a result of the Easter holidays falling in March this
year, revenue declined in March, but we retain our full-year organic growth
forecast of approximately 8% and still project an EBIT margin of 16-17%
measured at constant exchange rates," said Sten Scheibye, President and CEO.
